Syndax Pharmaceuticals Inc - Common Stock (SNDX)
CUSIP: 87164F105
Q2 2022 13F Holders as of 30 Jun 2022
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 86,727,396
- Total 13F shares
- 55,225,664
- Share change
- +857,024
- Total reported value
- $1,062,543,225
- Put/Call ratio
- 11%
- Price per share
- $19.24
- Number of holders
- 116
- Value change
- +$21,478,133
- Number of buys
- 56
- Number of sells
- 58
Quarterly Holders Quick Answers
What is CUSIP 87164F105?
CUSIP 87164F105 identifies SNDX - Syndax Pharmaceuticals Inc - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 87164F105:
Top shareholders of SNDX - Syndax Pharmaceuticals Inc - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Avidity Partners Management LP |
13F
|
Company |
5.6%
|
4,823,400
|
$83,831,000 | — | 31 Mar 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
4.4%
|
3,798,150
|
$66,011,000 | — | 31 Mar 2022 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
3.7%
|
3,195,403
|
$55,536,000 | — | 31 Mar 2022 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
3.1%
|
2,692,303
|
$46,792,000 | — | 31 Mar 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.8%
|
2,432,438
|
$42,277,000 | — | 31 Mar 2022 | |
| BVF INC/IL |
13F
|
Company |
2.8%
|
2,394,714
|
$41,620,000 | — | 31 Mar 2022 | |
| STATE STREET CORP |
13F
|
Company |
2.7%
|
2,380,337
|
$41,370,000 | — | 31 Mar 2022 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
2.6%
|
2,220,500
|
$38,592,000 | — | 31 Mar 2022 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
2.5%
|
2,158,300
|
$37,511,000 | — | 31 Mar 2022 | |
| PFM Health Sciences, LP |
13F
|
Company |
2.4%
|
2,043,377
|
$35,514,000 | — | 31 Mar 2022 | |
| Kynam Capital Management, LP |
13F
|
Company |
2.2%
|
1,932,800
|
$33,592,000 | — | 31 Mar 2022 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.1%
|
1,833,930
|
$31,873,000 | — | 31 Mar 2022 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.1%
|
1,825,440
|
$31,726,000 | — | 31 Mar 2022 | |
| 683 Capital Management, LLC |
13F
|
Company |
1.8%
|
1,581,653
|
$27,489,000 | — | 31 Mar 2022 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
1.5%
|
1,277,413
|
$22,201,000 | — | 31 Mar 2022 | |
| HealthCor Management, L.P. |
13F
|
Company |
1.4%
|
1,180,500
|
$20,517,000 | — | 31 Mar 2022 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
1,165,000
|
$20,248,000 | — | 31 Mar 2022 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.2%
|
1,078,641
|
$18,747,000 | — | 31 Mar 2022 | |
| Aisling Capital Management LP |
13F
|
Company |
1.2%
|
1,025,000
|
$17,815,000 | — | 31 Mar 2022 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1%
|
884,334
|
$15,370,000 | — | 31 Mar 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.99%
|
855,415
|
$14,867,000 | — | 31 Mar 2022 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
0.83%
|
717,064
|
$12,463,000 | — | 31 Mar 2022 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
0.81%
|
701,356
|
$12,190,000 | — | 31 Mar 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0.8%
|
697,688
|
$12,126,000 | — | 31 Mar 2022 | |
| Palo Alto Investors LP |
13F
|
Company |
0.71%
|
612,600
|
$10,647,000 | — | 31 Mar 2022 | |
| Phoenix Financial Ltd. |
13F
|
Company |
0.61%
|
525,856
|
$9,139,000 | — | 31 Mar 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.56%
|
486,228
|
$8,450,000 | — | 31 Mar 2022 | |
| NORGES BANK |
13F
|
Company |
0.56%
|
484,900
|
$8,427,562 | — | 31 Mar 2022 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.49%
|
426,113
|
$7,406,000 | — | 31 Mar 2022 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.47%
|
408,263
|
$7,095,000 | — | 31 Mar 2022 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.43%
|
371,987
|
$6,465,000 | — | 31 Mar 2022 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.42%
|
368,352
|
$6,402,000 | — | 31 Mar 2022 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.42%
|
360,000
|
$6,257,000 | — | 31 Mar 2022 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.39%
|
341,304
|
$5,932,000 | — | 31 Mar 2022 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
0.34%
|
293,349
|
$5,098,000 | — | 31 Mar 2022 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.28%
|
239,829
|
$4,168,000 | — | 31 Mar 2022 | |
| Ghost Tree Capital, LLC |
13F
|
Company |
0.26%
|
225,000
|
$3,911,000 | — | 31 Mar 2022 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.26%
|
224,058
|
$3,894,000 | — | 31 Mar 2022 | |
| UBS Group AG |
13F
|
Company |
0.25%
|
215,164
|
$3,740,000 | — | 31 Mar 2022 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.24%
|
209,835
|
$3,647,000 | — | 31 Mar 2022 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.24%
|
206,126
|
$3,582,000 | — | 31 Mar 2022 | |
| FMR LLC |
13F
|
Company |
0.22%
|
188,718
|
$3,280,000 | — | 31 Mar 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.21%
|
182,100
|
$3,165,000 | — | 31 Mar 2022 | |
| MACQUARIE GROUP LTD |
13F
|
Company |
0.21%
|
180,991
|
$3,145,000 | — | 31 Mar 2022 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.2%
|
176,391
|
$3,066,000 | — | 31 Mar 2022 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.19%
|
163,590
|
$2,773,000 | — | 31 Mar 2022 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.15%
|
130,479
|
$2,268,000 | — | 31 Mar 2022 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.14%
|
121,031
|
$2,104,000 | — | 31 Mar 2022 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.13%
|
115,094
|
$2,000,000 | — | 31 Mar 2022 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.13%
|
113,652
|
$1,975,000 | — | 31 Mar 2022 |
Institutional Holders of Syndax Pharmaceuticals Inc - Common Stock (SNDX) as of Q2 2022
As of 30 Jun 2022,
Syndax Pharmaceuticals Inc - Common Stock (SNDX) was held by
116 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
55,225,664 shares.
The largest 10 holders included
Avidity Partners Management LP, BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, Frazier Life Sciences Management, L.P., VANGUARD GROUP INC, Nantahala Capital Management, LLC, Kynam Capital Management, LP, STATE STREET CORP, BVF INC/IL, and ORBIMED ADVISORS LLC.
This page lists
116
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2022 vs Q1 2022 Across Filers
Q1 2022 holders
136
Q2 2022 holders
116
Holder diff
-20
| Investor | Q1 2022 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q1 2022 Value $ | Q2 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.